We are developing synthetic human hearts using 3D bioprinting technology.

We are still in the research and development stage. Our key research focus is currently on the development of a functional mini-heart that can be utilized for cardiotoxicity testing. Continued development relating to our other potential commercialization opportunities we are planning, including cardiac valves, patches, grafts, and ultimately a full heart viable for transplantation is currently curtailed as we focus on the mini-heart development, our initial commercialization opportunity. Our mini-heart, once optimized, will have four chambers, valves, greater vessels, musculature, electrical activity, and capable of generating intraluminal pressures. Currently, we have made significant progress towards the development and optimization of a functional mini-heart. We have been successful at bioprinting a heart, which has all four chambers needed for functional performance, and hence, for cardiotoxicity testing. The mini-heart has been populated with iPSC-CMs, cardiomyocytes that are derived from induced pluripotent stem cells. We are currently working on optimizing the final variables (i.e., printer settings, etc.) which we believe are necessary to successfully conduct cardiotoxicity testing and commercialize the mini-heart.

 As of the date of this Prospectus, we have not sold any products or generated any revenue from sales. Our products are currently in the preclinical development phase and have not yet received FDA clearance or approval. The FDA’s plans to regulate the 3D printing of human organs for use in implantation are currently unknown.

(Note: BioLife4D Corp. cut its unit IPO’s size to 1.3 million units – down from3.63 million units – and kept the price range at $5.20 to $7.20 – to raise $8.06 million, according to an S-1/A filing dated April 20, 2023. Background: BioLife4D filed an S-1/A dated Jan. 4, 2023, increasing the size of its unit IPO to 3.63 million units (3,627,053 units) at the same price range – $5.20 to $7.20 – to raise $22.49 million. The deal’s initial size was 2.41 million units (2,419,354 units) at $5.20 to $7.20, according to terms disclosed in an S-1/A  filing dated Nov. 15, 2022, to raise $15.0 million. Each unit consists of one share of common stock and two warrants – each to buy one share of common stock. BioLife4D Corp. filed its S-1 (prospectus) on June 3, 2022. The company’s IPO is a unit offering consisting of stock and warrants. Each unit consists of one share of common stock and one warrant to buy one share of common stock. Terms were not disclosed in the S-1 filing. The company has applied to list its common stock and warrants on the NASDAQ under the proposed symbol “SAVU” for the stock and “SAVUW” for the warrants. In an S-1/A filing dated June 17, 2022, BioLife4D Corp. said it also intends to offer pre-funded units to certain purchasers; please see the cover of the prospectus for details.)